Dare Bioscience, Inc. — Q1 2019 Form 10-Q
Business context and reporting period. The filing covers the three months ended March 31, 2019. Dare is a clinical-stage biopharmaceutical company focused on women’s health. It had no approved or commercialized products and generated no product revenue. Its pipeline included four clinical-stage and several preclinical candidates.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 or comparison |
|---|---|---|
| Revenue | None | None |
| Operating expenses | $3.08 million | $7.68 million; included $5.19 million goodwill impairment in 2018 |
| Research and development | $1.69 million | $1.09 million |
| Net loss | $3.05 million | $7.67 million |
| Basic and diluted loss per share | $0.27 | $0.88 |
| Cash used in operating activities | $3.31 million | $2.12 million |
| Cash and cash equivalents | $3.51 million at March 31 | $6.81 million at December 31, 2018 |
| Working capital | Approximately $3.2 million | |
| Total assets / liabilities / equity | $5.02 million / $1.24 million / $3.78 million |
Operating expenses fell year over year largely because the 2018 period included the goodwill impairment. R&D expense rose $607,000, reflecting increased development and staffing costs, partly offset by NIH grant funding. G&A was approximately flat. No operating or profit margins are meaningful because the company had no revenue and incurred losses.
No conventional borrowing was identified in the filing. Lease liabilities were $223,000, comprising $83,751 current and $139,288 non-current. The company reported an accumulated deficit of approximately $32.0 million and stated that substantial doubt existed about its ability to continue as a going concern.
Material changes and notable items
- Cash declined by $3.30 million during the quarter, with no financing proceeds in Q1 2019. Operating cash use increased compared with Q1 2018.
- In April 2019, after quarter-end, Dare raised approximately $5.2 million net from an offering of 5,261,250 shares. The offering increased the share count; 16,683,411 shares were issued and outstanding as of May 13, 2019, versus 11,422,161 at March 31.
- The April offering triggered an automatic reduction in the exercise price of warrants covering up to 3,720,500 shares, from $3.00 to $0.98 per share, creating potential additional dilution.
- Dare received a notice of award for an additional $982,851 in NIH funding for Ovaprene. A further $730,722 remained contingent on specified results and funding availability.
- The company adopted the lease accounting standard in January 2019 and recorded right-of-use assets and lease liabilities; it reported no resulting change to the statements of operations or cash flows.
Outlook, risks, and contingencies
- Management said available resources were expected to fund planned operations into Q1 2020, but also stated that resources were insufficient to meet working-capital and liquidity needs over at least the next 12 months from issuance of the financial statements. Additional capital is required; availability and terms are uncertain, and financing may dilute shareholders or require surrendering product rights.
- Planned 2019 work included Ovaprene’s postcoital clinical trial, a planned Phase 3 DARE-BV1 study, continued Phase 2b-related work for Sildenafil Cream, and a planned Phase 1 study for DARE-HRT1. Management expected DARE-BV1 Phase 3 to begin in Q4 2019 and, if successful, an NDA filing in 2020; Ovaprene study data were expected in the second half of 2019. These are forward-looking plans, not assurances.
- Management expected higher expenses as clinical programs advance. The company depends on additional funding, clinical and regulatory success, third parties for development and supply, and the retention of licensed rights. Failure to raise capital or achieve development milestones could delay or end programs or threaten continued operations.
- License agreements include potential milestone, royalty, and other payments. For example, Ovaprene’s agreement provides for up to $14.6 million in development and regulatory milestones and up to $20 million in sales milestones, plus royalties. Such payments are contingent; timing and occurrence are uncertain.
- The filing reported no material pending legal proceedings and no material changes to previously disclosed risk factors. Management stated that disclosure controls were effective as of March 31, 2019.
Important facts for investors to verify
- Whether the April offering proceeds and subsequent cash use provide adequate runway beyond management’s stated Q1 2020 estimate, given the filing’s substantial-doubt and 12-month liquidity disclosures.
- Whether Ovaprene study results and the planned DARE-BV1, Sildenafil Cream, and DARE-HRT1 milestones are achieved on the expected timelines and support regulatory progress.
- The extent of dilution from the April share issuance and the potential exercise of repriced warrants.
- The conditions and availability of remaining NIH grant funding, and future milestone, royalty, and license-payment obligations.